Ahmedabad-based Lincoln Pharmaceuticals Ltd., a global player in the formulations space, is targeting ₹1,000 crore in revenue over the next three years. This marks a nearly 55% increase from its current levels.
Focused Growth Strategy Across Key Segments
The company plans to grow at a yearly rate of 15–18%, driven by robust demand in the cardiac, diabetic, dermatology, and ENT segments. “We will grow 15–18 per cent yearly. So we are looking at roughly around ₹1,000 crore (in revenues) within the next three years,” said Munjal Patel, Whole-Time Director at Lincoln.
FY25 Performance and Market Footprint
In FY25, Lincoln Pharma reported a 5% year-on-year growth, with revenues reaching ₹647 crore. States such as Uttar Pradesh, Assam, and Odisha contributed significantly to its domestic sales performance. The company maintains a strong presence in 13 to 15 states across India. It plans to leverage further as part of its expansion strategy.
Strong Financial Health and Expansion Potential
Operating as a debt-free entity for the past five years, Lincoln Pharma is well-positioned to fund its growth through internal accruals. Its focus on high-growth therapeutic areas and a diversified state-wise presence supports the company’s confidence in achieving its ambitious revenue goal. As reported by thehindubusinessline.com, Lincoln Pharmaceuticals is gearing up for its next phase of growth. The company is building on a stable foundation and targeting new opportunities across India’s expanding healthcare market.
